This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Fluvirin, Influenza vaccine, trivalent influenza virus vaccine (TIVf)
Description: Fluvirin is a trivalent, subunit based seasonal influenza vaccine prepared using virally infected chicken eggs. Fluvian contains antigens from two different influenza A strains (one each from H1N1 and H2N3 strains) and one influenza B strain. The identity of the specific strains varies annually as determined by the USPHS based on which strains are most likely to be prevalent.
Novartis and CSL
In October 2014, Novartis entered into a definitive agreement to divest its influenza vaccines business to CSL Limited (CSL) for an agreed price of USD 275 million. This transaction requires regulatory approvals and is expected to close in the second half of 2015.
In August 2015, CSL announced that it has closed ts transaction to acquire Novartis global influenza vaccine business for a cash consideration of US$275 million.
Additional information available to subscribers only: